Effect of eicosapentaenoic acid/docosahexaenoic acid on coronary high-intensity plaques detected with non-contrast T1-weighted imaging (the AQUAMARINE EPA/DHA study): study protocol for a randomized controlled trial

Kazuhiro Nakao1, Teruo Noguchi1, Yasuhide Asaumi1, Yoshiaki Morita2, Tomoaki Kanaya1, Masashi Fujino1, Hayato Hosoda1, Shuichi Yoneda1, Shoji Kawakami1, Toshiyuki Nagai1, Kensaku Nishihira1, Takahiro Nakashima1, Reon Kumasaka1, Tetsuo Arakawa1, Fumiyuki Otsuka1, Michio Nakanishi1, Yu Kataoka1, Yoshio Tahara1, Yoichi Goto1, Haruko Yamamoto3, Toshimitsu Hamasaki4 and Satoshi Yasuda1*

Abstract

Background: Despite the success of HMG-CoA reductase inhibitor (statin) therapy in reducing atherosclerotic cardiovascular events, a residual risk for cardiovascular events in patients with coronary artery disease (CAD) remains. Long-chain n-3 polyunsaturated fatty acids (LC n-3 PUFAs), especially eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are promising anti-atherosclerosis agents that might reduce the residual CAD risk. Non-contrast T1-weighted imaging (T1WI) with cardiac magnetic resonance (CMR) less invasively identifies high-risk coronary plaques as high-intensity signals. These high-intensity plaques (HIPs) are quantitatively assessed using the plaque-to-myocardium signal intensity ratio (PMR). Our goal is to assess the effect of EPA/DHA on coronary HIPs detected with T1WI in patients with CAD on statin treatment.

Methods/design: This prospective, controlled, randomized, open-label study examines the effect of 12 months of EPA/DHA therapy and statin treatment on PMR of HIPs detected with CMR and computed tomography angiography (CTA) in patients with CAD. The primary endpoint is the change in PMR after EPA/DHA treatment. Secondary endpoints include changes in Hounsfield units, plaque volume, vessel area, and plaque area measured using CTA. Subjects are randomly assigned to either of three groups: the 2 g/day EPA/DHA group, the 4 g/day EPA/DHA group, or the no-treatment group.

Discussion: This trial will help assess whether EPA/DHA has an anti-atherosclerotic effect using PMR of HIPs detected by CMR. The trial outcomes will provide novel insights into the effect of EPA/DHA on high-risk coronary plaques and may provide new strategies for lowering the residual risk in patients with CAD on statin therapy.

(Continued on next page)
Background

Evidence strongly suggests that lowering low-density lipoprotein (LDL)-cholesterol levels with statins reduces the risk of cardiovascular disease as primary and secondary prevention of atherosclerotic cardiovascular events [1–7]. However, many clinical trials have found a significant residual risk for cardiovascular events even in the setting of optimal LDL-cholesterol reduction with statins [8, 9]. Thus, there is a need to establish strategies beyond lowering LDL-cholesterol levels with statins to reduce the risk of cardiovascular events.

Epidemiologic studies have shown that increasing the intake of long-chain n-3 polyunsaturated fatty acids (n-3 PUFAs), especially eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), is inversely associated with cardiovascular or cerebrovascular disease incidence [10–15]. The LC n-3 PUFAs have a different anti-atherosclerotic mechanism from statins, including triglyceride and remnant lipoprotein-lowering effects [16]. In experimental study, EPA/DHA treatments significantly attenuated the development and destabilization of atherosclerotic plaques [17]. Although meta-analysis failed to demonstrate the inhibitory effect of cardiovascular events by LC n-3 PUFA supplementation, the effects of high-dose LC n-3 PUFAs on cardiovascular outcome should be discussed (most previous and on-going studies use 1 g EPA/DHA) [18]. Indeed, higher-dose EPA (1.8 g) could reduce the residual risk of cardiovascular diseases in patients receiving LDL lowering with statins [19]. And previous human studies have investigated the effect of high-dose EPA on plaque stability or plaque composition [20, 21]. Therefore, the present study focuses on the effects of high-dose administration of EPA/DHA on coronary plaques.

We have reported that coronary high-intensity plaques (HIPs) detected with non-contrast T1-weighted imaging (T1WI) on cardiac magnetic resonance (CMR) are associated with computed tomography angiography (CTA) – and intravascular ultrasound-derived – features of high-risk plaques [22, 23]. HIPs, which can be uniquely assessed using the plaque-to-myocardium signal intensity ratio (PMR), [22] are significantly associated with future coronary events [24]. More recently, in the AQUAMARINE (Attempts at Plaque Vulnerability Quantification with Magnetic Resonance Imaging Using Non-contrast T1-weighted Technic) study, we have demonstrated that intensive lipid-lowering therapy with pitavastatin reduces the PMR of coronary HIPs by approximately 25% [25]. Thus, non-contrast T1WI is now being established as a less-invasive technique for evaluating high-risk coronary plaques, and as such, might be a promising predictive factor in patients at high risk.

The present AQUAMARINE-EPA/DHA study is designed to assess the anti-atherogenic effect of EPA/DHA in an exploratory manner. We will study the change in PMR of coronary HIPs detected using CMR after 12 months of EPA/DHA therapy.

Methods/design

Aim

The aim of this study is to assess the effect of EPA/DHA on PMR of HIPs in patients with coronary artery disease (CAD) detected using non-contrast T1WI imaging with CMR.

Study design

This is a single-center, triple-arm, parallel-group, randomized controlled, open-label, superiority trial examining the effect of 12 months of EPA/DHA therapy on coronary HIPs in patients with CAD between May 2014 and April 2018. Eligible subjects are randomly assigned to the 2 g/day EPA/DHA group, the 4 g/day EPA/DHA group, or the no-treatment group (allocation rate 1:1:1). The randomization stratified on following variables (age, gender, presence or absence of type 2 diabetes mellitus, and PMR of the primary coronary lesion measured with non-contrast T1WI) (Fig. 1).

Patient eligibility and recruitment

Patients aged 20 years or older with proven or suspected CAD receiving statin therapy are eligible for the study. It is necessary for eligible subjects to achieve an optimal LDL-cholesterol level (LDL-cholesterol < 100 mg/dl) recommended by the Japan Atherosclerosis Society. Patients are excluded if they are scheduled for percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) or had taken EPA/DHA within 12 weeks before providing informed consent, type 1 diabetes mellitus or type 2 diabetes mellitus with uncontrolled hyperglycemia (glycosylated hemoglobin (HbA1C) ≥ 8.0%), or the presence of bleeding (e.g., hemophilia, capillary fragility, gastrointestinal tract ulceration, urinary tract bleeding, hemoptyis, vitreous hemorrhage).
Study procedures
Eligible patients are randomly assigned to the 2 g/day EPA/DHA group, the 4 g/day EPA/DHA group, or the no-treatment group. Prospective, serial, non-contrast T1WI and CTA examinations are performed at baseline and after 12 months of EPA/DHA treatment (Fig. 2).

Inclusion and exclusion criteria

Inclusion criteria Subjects must meet all of the following criteria:

1. Be aged 20 years or older
2. Diagnosed with dyslipidemia and have received instructions for a 3–6-month lifestyle modification
3. Diagnosed with coronary artery disease with > 25% coronary stenosis measured by CTA or invasive coronary angiography (CAG)
4. On statin therapy at a fixed dose and administration method for at least 4 weeks before providing informed consent
5. Have at least one coronary plaque with PMR ≥ 1.0 with non-contrast T1WI on the screening examination
6. Serum LDL-cholesterol level < 100 mg/dL on the screening test
7. Capable of visiting the study centers on an outpatient basis
8. Capable of providing written consent before study participation

Exclusion criteria Those who meet any of the following criteria are ineligible for the study:

1. Use of LC n-3 PUFA preparations within 12 weeks before providing informed consent
2. Scheduled to undergo PCI or CABG during the observation period
3. Presence of type 1 diabetes mellitus or type 2 diabetes mellitus, with uncontrolled hyperglycemia (HbA1C ≥ 8.0%)
4. Clinically apparent impairment of renal function (estimated glomerular filtration rate < 40 ml/min)
5. Presence of bleeding (e.g., hemophilia, capillary fragility, gastrointestinal tract ulceration, urinary tract bleeding, hemoptysis, vitreous hemorrhage)
6. History of hypersensitivity to any component of the investigational product
7. Pregnancy, possible pregnancy, or nursing

Outcomes

Primary endpoint
The primary endpoint is the change in PMR of the primary coronary lesion measured by non-contrast, T1-weighted cardiac imaging from baseline to study completion or discontinuation (Table 1).

Secondary endpoint

1. Change in PMR in all lesions measured by non-contrast, T1-weighted CMR imaging from baseline to study completion or discontinuation
2. Percentage change in PMR of the primary lesion measured by non-contrast, T1-weighted CMR imaging from baseline to study completion or discontinuation
3. Percentage change in PMR of all lesions measured by non-contrast, T1-weighted CMR imaging from baseline to study completion or discontinuation
4. Change and percentage change in Hounsfield units, plaque volume, vessel area, and plaque area of the primary lesion measured by CTA from baseline to study completion or discontinuation

5. Change and percentage change in Hounsfield units, plaque volume, vessel area, and plaque area of all lesions measured by CTA from baseline to study completion or discontinuation

**Other variables**

1. Change and percentage change in triglycerides, total cholesterol, LDL-cholesterol, high-density lipoprotein (HDL)-cholesterol, non-HDL-cholesterol, very-low-density lipoprotein (VLDL)-cholesterol, remnant-like lipoprotein cholesterol, lipoprotein lipase (LPL) activity, and high-sensitivity C-reactive protein from baseline to study completion or discontinuation

2. Change and percentage change in small, dense LDL and mean LDL particle diameter from baseline to study completion or discontinuation (LDL diameter is measured using Lipoprint™ system (Quantrimetrix))

3. Change and percentage change in EPA, DHA, arachidonic acid (AA), EPA/AA ratio, and LC n-3 PUFA (percentage of EPA [C20:5ω3] and DHA [C22:6ω3] by weight in all fatty acids out of all lipids) from baseline to study completion or discontinuation

4. Change and percentage change in leptin and adiponectin from baseline to study completion or discontinuation

**Sample size**

Based on the result from our previous study, a clinically meaningful change from baseline in PMR was assumed to be \(-0.15\) in both the 2 g/day and the 4 g/day LC n-3 PUFA groups, and no change in the no-treatment group, with a common standard deviation of 0.2 among the groups. The sample size per group of 46 archives 90% power to detect the assumed difference in changes, using a two-group, one-sided \(t\) test of 1.25% significance level, where the overall significance level of the one-sided test for the two comparisons (i.e., the 2 g/day group versus the no-treatment group, and the 4 g/day LC n-3 PUFA group versus the no-treatment group) was
**Table 1** Summary of the study outcome and measures

| Primary endpoint | Change in PMR in the primary lesion measured by CMR imaging |
|------------------|-------------------------------------------------------------|
| Secondary endpoint | Change in PMR in all lesions measured by CMR imaging         |

Percentage change in PMR in the primary lesion measured by CMR imaging

Changes in Hounsfield units, plaque volume, vessel area, and plaque area in the primary lesion measured by CTA

Changes in Hounsfield units, plaque volume, vessel area, and plaque area in all lesions measured by CTA

Percentage changes in Hounsfield units, plaque volume, vessel area, and plaque area in the primary lesion measured by CTA

Percentage changes in Hounsfield units, plaque volume, vessel area, and plaque area in all lesions measured by CTA

**Other endpoint**

Changes and percentage changes in triglycerides, total cholesterol, LDL-cholesterol, HDL-cholesterol, non-HDL-cholesterol, VLDL-cholesterol, remnant-like cholesterol, LPL activity, and high-sensitivity C-reactive protein

Changes and percentage changes in small, dense LDL and mean LDL particle diameter

Changes and percentage changes in EPA, DHA, AA, EPA/AA ratio, and omega-3 index (weight percentage of eicosapentaenoic acid [EPA, C20:5ω3] and docosahexaenoic acid [DHA, C20:6ω3] in total fatty acids out of all lipids)

Changes and percentage changes in leptin and adiponectin

AA arachidonic acid, CMR cardiac magnetic resonance, CTA computed tomography angiography, HDL high-density lipoprotein, LDL low-density lipoprotein, LPL lipoprotein lipase, PMR plaque-to-myocardium signal intensity ratio, VLDL very-low density lipoprotein

2.5% and the Bonferroni adjustment was applied to control the Type I error rate. Allowing for adjustment of withdrawals, missing data or loss to follow-up, 50 subjects per group will be recruited into the trial.

**Randomization**

In this study, dynamic allocation is used in order to ensure an even allocation of factors that may influence the evaluation of the efficacy of anti-hypertensive medications. Dynamic allocation will be performed at the registration/allocation center at the start of therapy, with respect to age, gender, and presence or absence of type II diabetes. The allocation table and the most recent breakdown of allocated subjects in each group will be used for dynamic allocation at the registration/allocation center. However, this allocation table and the information regarding the number of allocated subjects in each group will not be disclosed to the study representative, principal investigator, or investigator until the completion of the study.

The SAS dynamic allocation system will be used for subject registration and allocation. In this system, web-based e-mails and the SAS server owned by the National Cerebral and Cardiovascular Center are used to automatically register and allocate subjects on a 24-h basis without any human operators.

The principal investigator or investigator will obtain consent for participation in the study from the subjects who they consider will have no problems in participation. After confirming that a subject meets all the eligibility criteria, the principal investigator or investigator will enter the necessary items in the portable document format (PDF) version of the registration form and send it to the SAS dynamic allocation system by e-mail for registration. The SAS dynamic allocation system will check the received registration form to see whether or not the eligibility criteria are met and whether or not the subject is already registered. If there are no problems, the system will allocate the subject using the randomized minimization method based on allocation adjustment factors. The results of the allocation will be automatically sent to the e-mail address used to send the registration form. The principal investigator or investigator will start the treatment based on the no-tification and record it on the Case Report Form (CRF) for each subject.

**Allocation factors**

Dynamic allocation is performed with respect to the following factors:

- Age at the time of consent: younger than 65 years/65 years or older
- Gender: male/female
- Concomitant type II diabetes: present/absent
- Plaque to myocardium ratio (PMR): below 1.35/1.35 or higher in non-contrast T1-weighted CMR images of the main lesion (a cut-off point of PMR that separates high risk from intermediate risk) [24, 26]

**Blinding**

All imaging and laboratory data will be analyzed by an independent attending physician and a radiologist at the National Cerebral and Cardiovascular Center (Japan), including CMR and CTA measurements. These evaluators will be blinded to patient treatment status.

**Data quality control and management**

The principal investigator or investigator must complete CRFs for each subject who provides written informed consent. The study representative or a person designated by the study representative will authorize access to the electronic CRF system for the principal investigator or investigator. CRFs will be prepared in Japanese. Data will be directly entered into the electronic CRF system during CRF preparation. The principal investigator or investigator will confirm that CRFs are accurately and completely prepared and register the data in the electronic CRF system and other systems. The principal investigator will
take full responsibility for the accuracy and reliability of all the data entered in the CRFs.

The completed CRFs are the property of the director of the study center. The principal investigator and other investigators must not disclose the information contained in the CRFs to third parties except for regulatory agencies without written approval from the director of the study center. Only investigators can access data.

**Statistical methods**

All the analysis will be made on an intent-to-treat (ITT) basis. The 2 g/day and the 4 g/day EPA/DHA groups will be compared against the no-treatment group for all primary analysis. For the primary outcome, treatment effects between the groups and their 95% confidence intervals are calculated from analysis of covariance (ANCOVA) models with adjustment for baseline values of the outcome measure. To confirm the conclusion from ITT-based analysis, the same analysis is repeated on a per-protocol set (PPS), where criteria for determining the PPS assignment would be established and confirmed by the Steering Committee. For secondary and other outcomes, we will use the chi-squared test for binary outcomes, and a t test for continuous outcomes. For subgroup analyses, we will use regression methods with appropriate interaction terms (respective subgroup x treatment group). Multivariable analyses will be based on logistic regression for binary outcomes and linear regression for continuous outcomes. We will examine the residual to assess model assumptions and goodness-of-fit.

All p values will be reported to four decimal places with p values less than 0.001 reported as p < 0.001. Up-to-date versions of SAS (SAS Institute, Cary, NC, USA) will be used to conduct analyses. For all tests, we will use two-sided p values with an alpha ≤ 0.05 level of significance.

**Study organization**

The research group consists of researchers and statisticians at the National Cerebral and Cardiovascular Center, Suita, Japan and an independent data monitoring committee.

**Monitoring**

Adverse events (AE) will be collected during the study periods. At each study visit, the principal investigator or investigator will interview the subject about whether any subjective symptoms have occurred. When an AE occurs, the principal investigator or investigator must promptly take appropriate measures and follow up all subjects experiencing an AE until the symptoms resolve, or any clinically significant abnormal laboratory values have returned to the baseline values. All AEs will be documented in the CRF. The Data Monitoring Committee is independent of the investigators. No interim analysis is planned.

**Definition of AEs**

An AE is defined as any untoward medical occurrence in a subject administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can, therefore, be any unfavorable or unintended sign (including a clinically significant laboratory abnormality), symptom, or disease temporally associated with the use of a drug whether or not it is considered related to the drug.

**Reporting of AEs**

When an AE occurs, the principal investigator or investigator must promptly take appropriate measures and follow up all subjects experiencing an AE until the symptoms resolve, or any clinically significant abnormal laboratory values have returned to baseline values, the addition to, or switching of, the investigational product, or there is a satisfactory explanation for the change (for AEs that are permanent or irreversible), regardless of whether the causal relationship of the AE with the investigational product. All AEs will be documented in the CRF. The following information will be documented for each AE: event term; dates of onset and disappearance; frequency; severity; causal relationship between the event and the investigational product (not related or related); action taken for the investigational product; outcome of event; and seriousness. For AEs that are considered to be unrelated to the investigational product, the reason for ruling out the causality should be documented in the comment column of the CRF.

**Discussion**

Although the results of many randomized controlled trials using statins have shown the usefulness of LDL-cholesterol-lowering therapy, the extent of coronary artery disease suppression did not exceed approximately 30% [27]. However, optimal management of residual risk following statin therapy is now emerging.

The LC n-3 PUFAs, especially EPA and DHA, exert pleiotropic cardiometabolic effects with a diverse range of actions. The LC n-3 PUFAs can ultimately reduce blood pressure, reduce platelet aggregation, and improve arterial and endothelial function. Importantly, LC n-3 PUFAs do not have a major effect on fasting total cholesterol and LDL-cholesterol levels; they effectively reduce triglyceride and remnant lipoprotein in hyperlipidemic patients [28]. Those effects of LC n-3 PUFAs are beneficial for the cardiovascular system. The present AQUAMARINE-EPA/DHA study is expected to clarify the effect of LC n-3 PUFAs on high-risk coronary plaques.
In the AQUAMARINE pilot study, we found that statin treatment reduces the PMR of coronary HIPs and that the reduction of PMR reflects improvement of high-risk features of HIPs under statin treatment. However, in many plaques, high PMR values remain (PMR > 1.0) even after statin treatment [25]. These results suggest that PMR measured by CMR can be useful not only to evaluate high-risk coronary plaques but also to assess coronary residual risks after statin treatment.

Therefore, this trial will provide novel insights into the effect of EPA/DHA therapy on residual risk in patients with CAD who are taking appropriate statin therapy.

Trial status
Period of patient recruitment: recruitment started in August 2015.

Additional file

Additional file 1: SPIRIT 2013 Checklist: recommended items to address in a clinical trial protocol and related documents. (DOC 119 kb)

Abbreviations
AA: Arachidonic acid; CAD: Coronary artery disease; CMR: Cardiac magnetic resonance; CRF: Case Report Form; CTA: Computed tomography angiography; DHA: Docosahexaenoic acid; EPA: Eicosapentaenoic acid; HDL: High-density lipoprotein; HIP: High-intensity plaque; LC n-3 PUFA: Long-chain n-3 polyunsaturated fatty acid; LDL: Low-density lipoprotein; LPL: Lipoprotein lipase; PCI: Percutaneous coronary intervention; PMR: Plaque-to-myocardium signal intensity ratio; T1WI: T1-weighted imaging; VLDL: Very-low-density lipoprotein

Acknowledgements
We give special thanks to all the patients participating in this study.

Funding
Funding for the study was provided by Takeda Pharmaceutical Co., Ltd. Funding No. OME-IIT-001 (142CR1-002).

Availability of data and materials
Not applicable.

Dissemination plans
Study findings will be presented in scientific conference and publications in medical journals. The investigators will prepare manuscripts for publications. The trial will be reported according to the Standard Protocol Items: Recommendation for Intervention Trials (SPIRIT) (see Additional file 1).

Authors’ contributions
SY is the principal investigator of this study; he will be primarily responsible for conducting the clinical trial, acquiring funding, and supervising the study. TN acquired ethics approval and designed the study. KN drafted and wrote the manuscript and is in charge of recruitment, participant management, and data collection. YM is responsible for CMR imaging. TH and HY advised on statistical analysis. YG supervised the study. YA, TK, MF, HH, SY, SK, TN, RK, TA, FO, MN, and YK are in charge of recruitment. All authors read and approved the final manuscript.

Ethics approval and consent to participate
This study will be conducted with the highest respect for each study participant according to the protocol. The ethical principles guiding the study have their origins in the Declaration of Helsinki and the Ethical Guidelines for Clinical Research (Ministry of Health, Labor, and Welfare, revised in 2008). This study was approved by the Hospital Ethics Committee of the National Cerebral and Cardiovascular Center and its Regional Committee (study no. M25-116). Written informed consent (including for publication) will be obtained before randomization in the usual manner. The investigators obtain informed consent from all participants. If the study protocol has to be modified after the beginning of the study, Ethics Committee approval will be needed.

Consent for publication
Written informed consent for publication will be obtained before randomization.

Competing interests
Dr. Y. K. reports receiving grants and personal fees from Takeda, personal fees from Daiichi-Sankyo, personal fees from Astra-Zeneca, grants and personal fees from Bristol-Myers, grants from Otsuka, and grants from Boehringer Ingel for work unrelated to this manuscript. The other authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, 5-7-1 Fujishiro-dai, Suita, Osaka 565-8565, Japan. 2Department of Radiology, National Cerebral and Cardiovascular Center, 5-7-1 Fujishiro-dai, Suita, Osaka 565-8565, Japan. 3Center for Advancing Clinical and Translational Science, National Cerebral and Cardiovascular Center, 5-7-1 Fujishiro-dai, Suita, Osaka 565-8565, Japan. 4Department of Data Science, National Cerebral and Cardiovascular Center, 5-7-1 Fujishiro-dai, Suita, Osaka 565-8565, Japan.

Received: 6 February 2017 Accepted: 24 November 2017
Published online: 08 January 2018

References
1. Johansson M, Jönsson B, Kjekshus J, Olsson AG, Pedersen TR, Wedel H. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group. N Engl J Med. 1997;336(5):332–6.
2. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, et al. The effect of pravastatin on coronary events after myoccardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335(14):1001–9.
3. Group HPSC. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7–22.
4. Ford I, Murray H, Packard CJ, Shepherd J, Macfarlane PW, Cobbe SM. Group WOSCPS. Long-term follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med. 2007;357(15):1477–86.
5. Downs JR, Cleefield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorffer A, Stein EA, Kruyer W, Goto AM. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279(20):1615–22.
6. Ridker PM, Danielson E, Fonseca FA, Genest J, Goto AM, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–207.
7. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes RJ, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–81.
8. Ridker PM, Genest J, Boekholdt SM, Libby P, Goto AM, Nordestgaard BG, Mora S, MacFadyen JG, Glynn R, Kastelein JJ, et al. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet. 2010;376(9738):333–9.
9. Mora S, Wenger NK, D’Amico DA, Breaux A, Boekholdt SM, Arsenault BJ, Deedwania P, Kastelein JJ, Waters DD. Determinants of residual risk in secondary prevention patients treated with high- versus low-dose statin therapy: the Treating to New Targets (TNT) study. Circulation. 2012;125(16):1979–87.
10. Kromhout D, Boschi-Pinto C, de Leenheer AP. The inverse relation between fish consumption and 20-year mortality from coronary heart disease. N Engl J Med. 1985;312(19):1205–9.
11. Siscovick DS, Raghunathan TE, King I, Weinmann S, Wicklund KG, Albright J, Bovbjerg V, Arbogast P, Smith H, Kushi LH. Dietary intake and cell membrane levels of long-chain n-3 polyunsaturated fatty acids and the risk of primary cardiac arrest. JAMA. 1995;274(17):1363–7.
12. Daviglus ML, Stamler J, Orencia AJ, Dyer AR, Liu K, Greenland P, Walsh MK, Morris D, Shekelle RB. Fish consumption and the 30-year risk of fatal myocardial infarction. N Engl J Med. 1997;336(15):1046–53.
13. Albert CM, Campos H, Stampfer MJ, Ridker PM, Manson JE, Willett WC, Ma J. Blood levels of long-chain n-3 fatty acids and the risk of sudden death. N Engl J Med. 2002;346(15):1113–8.
14. Hu FB, Bronner L, Willett WC, Stampfer MJ, Rexrode KM, Albert CM, Hunter D, Manson JE. Fish and omega-3 fatty acid intake and risk of coronary heart disease in women. JAMA. 2002;287(14):1815–21.
15. Hisamatsu T, Miura K, Ohkubo T, Yamamoto T, Fujiyoshi A, Miyagawa N, Kadota A, Takashina N, Okuda N, Yoshita K, et al. High long-chain n-3 fatty acid intake attenuates the effect of high resting heart rate on cardiovascular mortality risk: a 24-year follow-up of Japanese general population. J Cardiol. 2014;64(3):218–24.
16. Kromhout D, Yasuda S, Geleijnse JM, Shimokawa H. Fish oil and omega-3 fatty acids in cardiovascular disease: do they really work? Eur Heart J. 2012;33(4):436–43.
17. Takashima A, Fukuda D, Tanaka K, Higashikuni Y, Hirata Y, Nishimoto S, Yagi S, Yamada H, Soeki T, Wakatsuki T, et al. Combination of n-3 polyunsaturated fatty acids reduces atherogenesis in apolipoprotein E-deficient mice by inhibiting macrophage activation. Atherosclerosis. 2016;254:142.
18. Wen YT, Dai JH, Gao Q. Effects of Omega-3 fatty acid on major cardiovascular events and mortality in patients with coronary heart disease: a meta-analysis of randomized controlled trials. Nutr Metab Cardiovasc Dis. 2014;24(5):470–5.
19. Yokoyama M, Origa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, Okawa S, Sasaki J, Hishida H, Itakura H, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007;369(9567):1090–8.
20. Nishio R, Shinke T, Otake H, Nakagawa M, Nagoshi R, Inoue T, Kozuki A, Hariki H, Osue T, Taniguchi Y, et al. Stabilizing effect of combined eicosapentaenoic acid and statin therapy on coronary thin-cap fibroatheroma. Atherosclerosis. 2014;234(1):114–9.
21. Niki T, Wakatsuki T, Yamaguchi K, Taketani Y, Oeduka H, Kusunose K, Ise T, Iwase T, Yamada H, Soeki T, et al. Effects of the addition of eicosapentaenoic acid to strong statin therapy on inflammatory cytokines and coronary plaque components assessed by integrated backscatter intravascular ultrasound. Circ J. 2016;80(2):450–60.
22. Kawasaki T, Koga S, Koga N, Noguchi T, Tanaka H, Koga Y, Serikawa T, Orita Y, Ikeda S, Mitto T, et al. Characterization of hyperintense plaque with noncontrast T1-weighted cardiac magnetic resonance coronary plaque imaging: comparison with multislice computed tomography and intravascular ultrasound. JACC Cardiovasc Imaging. 2009;2(6):720–8.
23. Tanaka A, Kawasaki T, Noguchi T, Koga S, Hiramatsu Y, Fukuyama T, Koga N. Hyperintense plaque with noncontrast T1-weighted magnetic resonance coronary plaque imaging leading to acute coronary syndrome. Circulation. 2009;120(23):2400–1.
24. Noguchi T, Kawasaki T, Tanaka A, Yasuda S, Goto Y, Ishihara M, Nishimura K, Miyamoto Y, Node K, Koga N. High-intensity signals in coronary plaques on noncontrast T1-weighted magnetic resonance imaging as a novel determinant of coronary events. J Am Coll Cardiol. 2014;63(10):989–99.
25. Noguchi T, Tanaka A, Kawasaki T, Goto Y, Morita Y, Asaumi Y, Nakao K, Fujiwara R, Nishimura K, Miyamoto Y, et al. Effect of intensive statin therapy on coronary high-intensity plaques detected by noncontrast T1-weighted imaging: the AQUAMARINE pilot study. J Am Coll Cardiol. 2011;56(3):245–56.
26. Asaumi Y, Noguchi T, Morita Y, Fujiwara R, Kanaya T, Matsuyama TA, Kawasaki T, Fujiwara M, Yamanaka T, Nagai T, et al. High-intensity plaques on noncontrast T1-weighted imaging as a predictor of periprocedural myocardial injury. JACC Cardiovasc Imaging. 2015;8(6):741–3.
27. Sampson UK, Fazo S, Linton MF. Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges. Curr Atheroscler Rep. 2012;14(1):1–10.
28. Nakamura N, Hamazaki T, Hotta M, Okuda K, Urakaze M, Sawazaki S, Yamasaki K, Sato T, Temaru R, Ishikura Y, et al. Joint effects of HMG-CoA reductase inhibitors and eicosapentaenoic acids on serum lipid profile and plasma fatty acid concentrations in patients with hyperlipidemia. Int J Clin Lab Res. 1999;29(1):22–5.